• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

台湾黏多糖贮积症患者的眼科表现

Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses.

作者信息

Lin Hsiang-Yu, Chan Wei-Chun, Chen Lee-Jen, Lee Yuan-Chieh, Yeh Shu-I, Niu Dau-Ming, Chiu Pao Chin, Tsai Wen-Hui, Hwu Wuh-Liang, Chuang Chih-Kuang, Lin Shuan-Pei

机构信息

Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.

Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.

出版信息

Mol Genet Genomic Med. 2019 May;7(5):e00617. doi: 10.1002/mgg3.617. Epub 2019 Mar 8.

DOI:10.1002/mgg3.617
PMID:30848093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6503066/
Abstract

BACKGROUND

Mucopolysaccharidoses (MPSs) are a group of rare lysosomal storage disorders characterized by the accumulation of glycosaminoglycans in various tissues and organs. Ocular problems that affect the cornea, trabecular meshwork, sclera, retina, and optic nerve are very common in these patients. However, there was limited literature focusing on comprehensive ocular findings in different types of MPS.

METHODS

We retrospectively reviewed the clinical ophthalmologic features and electrodiagnostic results of 50 Taiwanese patients with a diagnosis of MPS (34 males and 16 females; age range, 1.1-34.9 years; nine with MPS I, 17 with MPS II, 17 with MPS IV, and seven with MPS VI).

RESULTS

Among 44 patients with available data for visual acuity, 15 patients (34%) had a visual acuity of less than 0.5 (6/12) equivalent in their better eye, including 71% of those with MPS VI, 38% with MPS IV, 29% with MPS I, and 14% with MPS II. Severe corneal opacities existed in 57% of MPS VI patients and 11% of MPS I patients, compared with none for MPS II and MPS IV patients. Among 80 eyes with available data of refraction, 11 eyes (14%) had myopia (≦-0.50 D), 55 eyes (69%) had hyperopia (≧0.50 D), and 55 eyes (69%) had high astigmatism (≧1.50 D). Ocular hypertension was found in 45% (28/62) of eyes. There were 16% (14/90), 11% (10/90), 13% (12/90), 31% (27/86), and 79% (30/38) of MPS eyes with lens opacities, optic disc swelling, optic disc cupped, retinopathy, and visual pathway dysfunction, respectively. Intraocular pressure was positively correlated with the severity of corneal opacity (p < 0.01).

CONCLUSIONS

Ocular complications with significant reduction in visual acuity are common in MPS patients. Diagnostic problems may arise in these patients with severe corneal opacification, especially for those with MPS VI and MPS I.

摘要

背景

黏多糖贮积症(MPSs)是一组罕见的溶酶体贮积病,其特征是糖胺聚糖在各种组织和器官中蓄积。影响角膜、小梁网、巩膜、视网膜和视神经的眼部问题在这些患者中非常常见。然而,专注于不同类型MPS综合眼部表现的文献有限。

方法

我们回顾性分析了50例诊断为MPS的台湾患者的临床眼科特征和电诊断结果(34例男性和16例女性;年龄范围1.1 - 34.9岁;9例为MPS I型,17例为MPS II型,17例为MPS IV型,7例为MPS VI型)。

结果

在44例有视力数据的患者中,15例(34%)较好眼的视力低于0.5(6/12),其中MPS VI型患者中有71%,MPS IV型患者中有38%,MPS I型患者中有29%,MPS II型患者中有14%。57%的MPS VI型患者和11%的MPS I型患者存在严重角膜混浊,而MPS II型和MPS IV型患者均无。在80只可获得屈光数据的眼中,11只眼(14%)为近视(≦ - 0.50 D),55只眼(69%)为远视(≧0.50 D),55只眼(69%)有高度散光(≧1.50 D)。45%(28/62)的眼发现有高眼压。MPS患者中分别有16%(14/90)、11%(10/90)、13%(12/90)、31%(27/86)和79%(30/38)的眼有晶状体混浊、视盘肿胀、视盘杯状凹陷、视网膜病变和视觉通路功能障碍。眼压与角膜混浊的严重程度呈正相关(p < 0.01)。

结论

MPS患者常见视力显著下降的眼部并发症。这些严重角膜混浊的患者可能会出现诊断问题,尤其是MPS VI型和MPS I型患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/9ec02173d006/MGG3-7-e00617-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/c21cdf5176c4/MGG3-7-e00617-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/c2030897e1fd/MGG3-7-e00617-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/230a84430660/MGG3-7-e00617-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/d0b5ac82f261/MGG3-7-e00617-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/9ec02173d006/MGG3-7-e00617-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/c21cdf5176c4/MGG3-7-e00617-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/c2030897e1fd/MGG3-7-e00617-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/230a84430660/MGG3-7-e00617-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/d0b5ac82f261/MGG3-7-e00617-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8bc/6503066/9ec02173d006/MGG3-7-e00617-g005.jpg

相似文献

1
Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses.台湾黏多糖贮积症患者的眼科表现
Mol Genet Genomic Med. 2019 May;7(5):e00617. doi: 10.1002/mgg3.617. Epub 2019 Mar 8.
2
The ocular features of the mucopolysaccharidoses.黏多糖贮积症的眼部特征。
Eye (Lond). 2006 May;20(5):553-63. doi: 10.1038/sj.eye.6701921.
3
Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux-Lamy syndrome).台湾黏多糖贮积症VI型(马罗-拉米综合征)患者的临床眼部表现。
Taiwan J Ophthalmol. 2019 Sep 12;9(3):194-197. doi: 10.4103/tjo.tjo_85_17. eCollection 2019 Jul-Sep.
4
[Ocular findings in patients with mucopolysaccharidosis].[黏多糖贮积症患者的眼部表现]
Arq Bras Oftalmol. 2011 Nov-Dec;74(6):430-4. doi: 10.1590/s0004-27492011000600010.
5
Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis.儿童黏多糖贮积症眼部表现的诊断和管理临床指南。
Acta Ophthalmol. 2012 Nov;90(7):595-602. doi: 10.1111/j.1755-3768.2011.02280.x. Epub 2011 Dec 2.
6
Mucopolysaccharidoses and the eye.黏多糖贮积症与眼睛。
Surv Ophthalmol. 2006 Jan-Feb;51(1):1-17. doi: 10.1016/j.survophthal.2005.11.007.
7
Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses.系统性黏多糖贮积症中的视神经乳头水肿和视神经萎缩。
Ophthalmology. 1990 Nov;97(11):1445-9. doi: 10.1016/s0161-6420(90)32400-4.
8
Ocular features in mucopolysaccharidosis: diagnosis and treatment.黏多糖贮积症的眼部特征:诊断与治疗。
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):125. doi: 10.1186/s13052-018-0559-9.
9
Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985-2019).175 例台湾黏多糖贮积症患者的生存和诊断年龄(1985-2019 年)。
Orphanet J Rare Dis. 2020 Nov 7;15(1):314. doi: 10.1186/s13023-020-01598-z.
10
Corneal hysteresis in mucopolysaccharidosis I and VI.黏多糖贮积症 I 型和 VI 型的角膜滞后性。
Acta Ophthalmol. 2012 Aug;90(5):445-8. doi: 10.1111/j.1755-3768.2010.02085.x. Epub 2011 Jan 14.

引用本文的文献

1
The Role of Visual Electrophysiology in Systemic Hereditary Syndromes.视觉电生理在系统性遗传性综合征中的作用
Int J Mol Sci. 2025 Jan 23;26(3):957. doi: 10.3390/ijms26030957.
2
Novel Fundoscopic Features in Mucopolysaccharidosis Type VI: Multimodal Evaluation of Scleral Deposits.VI型黏多糖贮积症的新型眼底镜特征:巩膜沉积物的多模态评估
Case Rep Ophthalmol. 2024 Aug 13;15(1):642-647. doi: 10.1159/000540015. eCollection 2024 Jan-Dec.
3
The diagnosis and management of mucopolysaccharidosis type II.黏多糖贮积症 II 型的诊断与治疗。

本文引用的文献

1
Assessment and diagnosis of suspected glaucoma in patients with mucopolysaccharidosis.黏多糖贮积症患者疑似青光眼的评估与诊断
Acta Ophthalmol. 2015 Mar;93(2):e111-7. doi: 10.1111/aos.12607.
2
An update on ocular involvement in mucopolysaccharidoses.黏多糖贮积症眼部病变的最新进展。
Curr Opin Ophthalmol. 2013 Sep;24(5):379-88. doi: 10.1097/ICU.0b013e3283644ea1.
3
[Ocular findings in children with mucopolysaccharidosis].[黏多糖贮积症患儿的眼部表现]
Ital J Pediatr. 2024 Oct 8;50(1):207. doi: 10.1186/s13052-024-01769-9.
4
Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.转铁蛋白受体靶向艾杜糖-2-硫酸酯酶穿透血视网膜屏障并改善黏多糖贮积症 II 型小鼠的视网膜病变。
Mol Pharm. 2023 Nov 6;20(11):5901-5909. doi: 10.1021/acs.molpharmaceut.3c00736. Epub 2023 Oct 20.
5
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.硫酸乙酰肝素及其在黏多糖贮积症中的生物标志物作用的致病角色。
Int J Mol Sci. 2022 Oct 3;23(19):11724. doi: 10.3390/ijms231911724.
6
Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis.静脉注射阿加糖酶α治疗ⅣA型黏多糖贮积症的疗效:一项系统评价和荟萃分析。
J Pers Med. 2022 Aug 20;12(8):1338. doi: 10.3390/jpm12081338.
7
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.艾度硫酸酯酶 α 在治疗黏多糖贮积症 A 型中的临床应用
Drug Des Devel Ther. 2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.
8
Glaucoma in mucopolysaccharidoses.黏多糖贮积症相关青光眼。
Orphanet J Rare Dis. 2021 Jul 15;16(1):312. doi: 10.1186/s13023-021-01935-w.
9
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.黏多糖贮积症 I 型:当前的治疗方法、局限性和改进的前景。
Biomolecules. 2021 Jan 29;11(2):189. doi: 10.3390/biom11020189.
10
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.黏多糖贮积症 I 型:自然病史和分子病理学综述。
Cells. 2020 Aug 5;9(8):1838. doi: 10.3390/cells9081838.
Rev Med Inst Mex Seguro Soc. 2012 Sep-Oct;50(5):523-8.
4
The role of visual electrophysiology in mucopolysaccharidoses.视觉电生理学在黏多糖贮积症中的作用。
J Child Neurol. 2013 Oct;28(10):1203-9. doi: 10.1177/0883073812453322. Epub 2012 Aug 21.
5
Self-reported myopia in Taiwan: 2005 Taiwan National Health Interview Survey.台湾的自我报告近视情况:2005 年台湾全国健康访谈调查。
Eye (Lond). 2012 May;26(5):684-9. doi: 10.1038/eye.2012.9. Epub 2012 Feb 17.
6
[Ocular findings in patients with mucopolysaccharidosis].[黏多糖贮积症患者的眼部表现]
Arq Bras Oftalmol. 2011 Nov-Dec;74(6):430-4. doi: 10.1590/s0004-27492011000600010.
7
Ocular manifestations as key features for diagnosing mucopolysaccharidoses.眼部表现作为诊断黏多糖贮积症的关键特征。
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v34-40. doi: 10.1093/rheumatology/ker392.
8
Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis.儿童黏多糖贮积症眼部表现的诊断和管理临床指南。
Acta Ophthalmol. 2012 Nov;90(7):595-602. doi: 10.1111/j.1755-3768.2011.02280.x. Epub 2011 Dec 2.
9
[Ocular manifestations in patients affected by Morquio syndrome (MPS IV)].[黏多糖贮积症IV型(莫尔基奥综合征)患者的眼部表现]
J Fr Ophtalmol. 2010 Nov;33(9):617-22. doi: 10.1016/j.jfo.2010.09.008. Epub 2010 Nov 3.
10
Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis.黏多糖贮积症患者眼科特征的诊断与治疗。
Br J Ophthalmol. 2011 May;95(5):613-9. doi: 10.1136/bjo.2010.179937. Epub 2010 Sep 18.